Long
Possible H&S, after FDA approval for fast track consideration?
The MACD and RSI looks a little overbought. Also the upcoming FDA approval, is not for usage of the drug. But just a Phase 3 fast track evaluation of the drug. Which would take another few months, before an actual approval.
Am expecting a likely correction, which I would buy in a bit more.
On the long term, am bullish of this drug and the tumour imaging agent, it has bought rights for.
Am expecting a likely correction, which I would buy in a bit more.
On the long term, am bullish of this drug and the tumour imaging agent, it has bought rights for.
Note
Looks like not much chance of a major correction, with more institutional investors coming in.Note
Seems like a correction till 2.20
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.